DKP Critical Insights® Syndicated Reports

DKP has developed a series of syndicated reports to provide perspectives into the oncology and rare-disease environment. The reports are designed to help you inform short- and long-term strategies that will support market positioning of your portfolio, as well as ongoing patient access to care.

State Cancer Drug Parity Legislation – Oral vs. IV
  • Receive quick access to state-specific oral and IV cancer drug parity legislation information
  • Identify cost-sharing requirements, limitations, and other provisions for each formulation by state
  • Understand how legislative provisions can vary by geography
  • Determine whether states with this type of legislation treat oral and IV products equally
Click here for more information

We'd love to help you. Give us a call at (317) 873-0303.

Send us a message
  • This field is for validation purposes and should be left unchanged.